CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Newsmakers
CytoDyn’s (OTC: CYDY) Monotherapy Trial with Leronlimab (PRO 140) Reaches its Ultimate Goals
New data shows 525 mg dose achieves 95% response rate after the first 10 weeks of monotherapy with leronlimab Over 110 patients have reached almost one year of suppressed viral load with monotherapy on original […]
Healthcare
CytoDyn (OTC: CYDY) Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure
VANCOUVER, Washington, Jan 27, 2020 — The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has […]
Healthcare
CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA
VANCOUVER, Washington, Jul 25, 2019– – FDA face-to-face meeting granted to discuss pivotal monotherapy trial – Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. […]